Breast Cancer

Accelerated vs Standard Epirubicin and Capecitabine vs CMF in Breast Cancer

The phase III UK TACT2 trial has shown no efficacy benefit of accelerated vs standard epirubicin and a potential quality-of-life benefit of capecitabine vs CMF...

CNS Cancers

Dinutuximab vs Temsirolimus in Combination Therapy for Children With Resistant Neuroblastoma

A randomized phase II trial (Children’s Oncology Group [COG] ANBL1221) has resulted in the selection of dinutuximab plus irinotecan/temozolomide...

Colorectal Cancer

First-Line Cetuximab vs Bevacizumab Plus Chemotherapy in KRAS Wild-Type Colorectal Cancer

A phase III trial has shown no significant difference in overall survival with first-line cetuximab vs bevacizumab plus chemotherapy...


Advertisement

More Top Stories

Colorectal Cancer

Temidayo Fadelu, MD, on Colon Cancer: Results From the CALGB 89803 Trial

Edith Peterson Mitchell, MD, Awarded ASTRO Honorary Membership

Edith Peterson Mitchell, MD, a leading researcher, medical oncologist, and proponent of combined-modality treatment, has been chosen as the 2017 American Society for Radiation Oncology (ASTRO) Honorary Member. Dr. Mitchell will receive this award—which is the highest honor ASTRO awards to...

Advertisement

Tibetan Yoga Practice May Improve Sleep Quality for Patients With Breast Cancer Undergoing Chemotherapy

Participating in twice-weekly practice of Tibetan yoga may reduce sleep disturbances and improve sleep quality in breast cancer patients receiving chemotherapy, according to a study published by Chaoul et al in Cancer. The study, led by researchers from The University of Texas MD Anderson Cancer...

Prostate Cancer

Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the LATITUDE Trial

Thyroid Cancer

The Rising Incidence of Thyroid Cancer Reconsidered

Despite a significant rise in the incidence of thyroid cancer, the U.S. Preventive Services Task Force (USPSTF), a panel of independent experts in primary care and screening, has given thyroid cancer screening a D recommendation, which is a recommendation against screening. To shed light on this...

Geriatric Oncology

Register for the Geriatric Oncology Workshop

On November 6, 2017, ASCO and the U.S. Food and Drug Administration (FDA) will hold a joint Geriatric Oncology Workshop aimed at improving the evidence base for treating the geriatric oncology population.  While more than 60% of cancers in the United States occur in people aged 65 and older, the...

Positive Results from Phase III MURANO Trial Evaluating Venetoclax in Combination With Rituximab in Relapsed/Refractory CLL

The phase III MURANO study of venetoclax (Venclexta) tablets in combination with rituximab (Rituxan) met its primary endpoint. Results showed that the combination prolonged progression-free survival in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared with bendamustine...

Issues in Oncology
Legislation

Xuesong Han, PhD, on Early-Stage Diagnosis and the Affordable Care Act: An Epidemiologic Study

Legislation

FDA Announces New Comprehensive Plan for Tobacco and Nicotine Regulation

Recently, the U.S. Food and Drug Administration (FDA) announced a new strategy to address tobacco-related disease and death. The agency seeks to develop a plan to reduce the nicotine levels in combustible cigarettes to nonaddictive levels. However, as part of the strategy, the FDA also announced it ...

Advertisement

Overall Survival With Nivolumab/Ipilimumab, or Nivolumab Alone, vs Ipilimumab in Advanced Melanoma

Overall survival outcomes in the phase III CheckMate 067 trial indicate improved survival with nivolumab (Opdivo)/ipilimumab (Yervoy) vs ipilimumab and with nivolumab vs ipilimumab in patients with previously untreated advanced melanoma. These findings were reported in The New England Journal of...